CREB5 and head and neck squamous cell carcinoma: In summary, our study demonstrated that the novel CREB5/TOP1MT axis promotes cisplatin resistance in HNSCC cells through inhibiting mitochondrial apoptosis, and this double-targeting therapy provides a new avenue for treating cisplatin-resistant patients.